Carafate

Sucralfate
Clinical data

Trade names	Carafate
AHFS/Drugs.com	Monograph
MedlinePlus	a681049
Pregnancy category	B
Routes of administration	, suspension, rectal suspension
ATC code	A02BX02 (WHO)
Legal status
Legal status	℞ (Prescription only)
Pharmacokinetic data
Bioavailability	3-5% (local acting)
Metabolism	GI; liver: unknown
Biological half-life	unknown
Excretion	feces, urine
Identifiers
IUPAC name Hexadeca-μ-hydroxytetracosahydroxy[μ₈-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
CAS Number	54182-58-0^Y
PubChem CID	6398525
DrugBank	DB00364^N
ChemSpider	4911161^N
UNII	XX73205DH5
ChEMBL	CHEMBL611727^N
ECHA InfoCard	100.053.636
Chemical and physical data
Formula	C₁₂H₅₄Al₁₆O₇₅S₈
Molar mass	2086.75 g/mol
^NY (what is this?)

Sucralfate is a medication primarily taken to treat active duodenal ulcers. Sucralfate is also used for the treatment of gastroesophageal reflux disease (GERD) and stress ulcers.

Sucralfate is a sucrose sulfate-aluminium complex that binds to the ulcer, creating a physical barrier that protects the gastrointestinal tract from stomach acid and prevents the degradation of mucus. It also promotes bicarbonate production and acts like an acid buffer with cytoprotective properties.

Sucralfate is used for the treatment of active duodenal ulcers not related to the use of nonsteroidal anti-inflammatory drugs (NSAIDs), as the mechanism behind these ulcers is due to acid oversecretion. It is not FDA approved for gastric ulcers, as the main mechanism is not due to acid oversecretion but rather from diminished protection. The use for sucralfate in peptic ulcer disease has diminished recently, but it is still the preferred agent for stress ulcer prevention.

Sucralfate has also been used for the following conditions:

The most common side effect seen is constipation (2-3%). Less commonly reported side effects (<0.5%) include flatulence, headache, hypophosphatemia, xerostomia (dry mouth), and bezoar formation. Avoid using this drug in people with chronic kidney failure, as it might cause aluminium accumulation and toxicity. There is a limited number of well-controlled studies investigating the safety and efficacy of sucralfate in children and pregnant women (Pregnancy Category B).

...
Wikipedia